Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries
Acute myeloid leukemia (AML) presents a significant global health challenge due to its aggressive behavior and mortality rates. Traditionally, AML treatment has relied on intensive chemotherapy—anthracyclines and cytarabine. However, recent breakthroughs in targeted therapies are transforming clinic...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/5/1221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327593779625984 |
|---|---|
| author | Michelle Morcos-Sandino Sofia Isabel Quezada-Ramírez Andrés Gómez-De León |
| author_facet | Michelle Morcos-Sandino Sofia Isabel Quezada-Ramírez Andrés Gómez-De León |
| author_sort | Michelle Morcos-Sandino |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) presents a significant global health challenge due to its aggressive behavior and mortality rates. Traditionally, AML treatment has relied on intensive chemotherapy—anthracyclines and cytarabine. However, recent breakthroughs in targeted therapies are transforming clinical practices. This review examines current treatment strategies, including breakthrough therapies. Also, a global perspective on AML management includes the disparity in treatment availability, particularly the difficulties faced by low- and middle-income countries due to the high cost and restricted access to novel therapies. |
| format | Article |
| id | doaj-art-e334de0b7315431c9defc07735a3c604 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-e334de0b7315431c9defc07735a3c6042025-08-20T03:47:49ZengMDPI AGBiomedicines2227-90592025-05-01135122110.3390/biomedicines13051221Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income CountriesMichelle Morcos-Sandino0Sofia Isabel Quezada-Ramírez1Andrés Gómez-De León2Hematology Service, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León (UANL), Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey ZC 64460, Nuevo León, MexicoHematology Service, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León (UANL), Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey ZC 64460, Nuevo León, MexicoHematology Service, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León (UANL), Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey ZC 64460, Nuevo León, MexicoAcute myeloid leukemia (AML) presents a significant global health challenge due to its aggressive behavior and mortality rates. Traditionally, AML treatment has relied on intensive chemotherapy—anthracyclines and cytarabine. However, recent breakthroughs in targeted therapies are transforming clinical practices. This review examines current treatment strategies, including breakthrough therapies. Also, a global perspective on AML management includes the disparity in treatment availability, particularly the difficulties faced by low- and middle-income countries due to the high cost and restricted access to novel therapies.https://www.mdpi.com/2227-9059/13/5/1221acute myeloid leukemianewly diagnosedrelapsed or refractoryintensive chemotherapyhypomethylatingBLC-2 Inhibitor |
| spellingShingle | Michelle Morcos-Sandino Sofia Isabel Quezada-Ramírez Andrés Gómez-De León Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries Biomedicines acute myeloid leukemia newly diagnosed relapsed or refractory intensive chemotherapy hypomethylating BLC-2 Inhibitor |
| title | Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries |
| title_full | Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries |
| title_fullStr | Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries |
| title_full_unstemmed | Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries |
| title_short | Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries |
| title_sort | advances in the treatment of acute myeloid leukemia implications for low and middle income countries |
| topic | acute myeloid leukemia newly diagnosed relapsed or refractory intensive chemotherapy hypomethylating BLC-2 Inhibitor |
| url | https://www.mdpi.com/2227-9059/13/5/1221 |
| work_keys_str_mv | AT michellemorcossandino advancesinthetreatmentofacutemyeloidleukemiaimplicationsforlowandmiddleincomecountries AT sofiaisabelquezadaramirez advancesinthetreatmentofacutemyeloidleukemiaimplicationsforlowandmiddleincomecountries AT andresgomezdeleon advancesinthetreatmentofacutemyeloidleukemiaimplicationsforlowandmiddleincomecountries |